Carcinogenesis of β-Propiolactone: A Computational Study

Eva Španinger1, Urban Bren1

  • 1Laboratory of Physical Chemistry and Chemical Thermodynamics, Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, SI-2000 Maribor, Slovenia.

Insights

Beta-propiolactone (BPL) can damage DNA, but glutathione may protect against its harmful effects. Computer simulations reveal how BPL reacts with DNA bases and glutathione.

Area of Science:

  • Computational chemistry
  • Toxicology
  • Molecular biology

Background:

  • Beta-propiolactone (BPL) is a potential human carcinogen linked to tumor formation in animals.
  • Despite risks, BPL is used in vaccines for viral inactivation due to its efficacy.
  • Understanding BPL's reaction mechanisms is crucial for assessing its safety and applications.

Purpose of the Study:

  • To investigate the reaction mechanisms of BPL with DNA nucleobases and glutathione (GSH).
  • To elucidate the molecular interactions using quantum chemical methods and computer simulations.
  • To evaluate the potential protective role of GSH against BPL-induced DNA damage.

Main Methods:

  • Quantum chemical calculations were employed to simulate BPL reactions.
  • Solvent effects were incorporated to determine activation energies.
  • Reaction pathways (alkylation vs. acylation) and adduct formation were analyzed.

Main Results:

  • Guanine showed the highest reactivity towards BPL, forming adducts via an SN2 mechanism.
  • Alkylation was found to be energetically more favorable than acylation for all nucleobases.
  • Glutathione exhibited a high scavenging potential for BPL, comparable to guanine.

Conclusions:

  • Glutathione may act as a natural scavenger, protecting DNA from BPL.
  • This protective mechanism could mitigate BPL's genotoxicity, mutagenicity, and carcinogenicity.
  • The findings support the potential use of BPL in specific applications while highlighting protective biological mechanisms.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
340
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
15.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
173